Clinical Trial Readiness for SCA1 and SCA3
Enrolling By Invitation
18 years - 65 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
The prospective study is to establish the world's largest cohort of premanifest and early-stage SCA1 and SCA3 individuals.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: SCA1 SCA3,SCA1 ,SCA3
-
Age: 18 years - 65 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833946
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
